Related Experiment Video
Updated: Apr 5, 2026
09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
9.9K
Thrombosis, Microangiopathies, and Inflammation
Karen Matevosyan1, Ravi Sarode1
1Division of Transfusion Medicine and Hemostasis, Department of Pathology, UT Southwestern Medical Center, Dallas, Texas.
Seminars in Thrombosis and Hemostasis
|August 16, 2015
Summary
Thrombotic microangiopathy (TMA) involves microangiopathic hemolytic anemia and thrombocytopenia. This review covers key developments in understanding the causes, diagnosis, and treatment of common TMAs like TTP and aHUS.
Area of Science:
- Hematology
- Pathology
- Immunology
Background:
- Thrombotic microangiopathy (TMA) is a condition characterized by microangiopathic hemolytic anemia and thrombocytopenia.
- Neutrophils and their extracellular traps (NETs) play a role in TMA pathogenesis.
- Key TMAs include thrombotic thrombocytopenic purpura (TTP) due to ADAMTS-13 deficiency and atypical hemolytic uremic syndrome (aHUS) linked to complement dysregulation.
Purpose of the Study:
- To review recent advancements in the etiopathogenesis, diagnosis, and treatment of commonly encountered TMAs.
- To highlight the importance of differentiating various TMA causes for appropriate management.
- To discuss the role of neutrophil extracellular traps in TMA.
Main Methods:
- Literature review of recent studies on TMA.
- Analysis of current understanding of TTP and aHUS pathogenesis.
- Discussion of diagnostic approaches and evolving treatment strategies for TMAs.
Main Results:
- Significant progress has been made in understanding the molecular mechanisms underlying TTP and aHUS.
- Improved diagnostic tools allow for more precise identification of TMA subtypes.
- Treatment strategies for TMAs have evolved, with better outcomes reported.
Conclusions:
- TMAs encompass diverse disorders with genetic and acquired causes, requiring thorough investigation.
- Understanding the specific etiology of TMA is crucial for selecting effective therapies.
- Continued research into TMA pathogenesis, including the role of NETs, is essential for further therapeutic advancements.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
01:30Venous Thrombosis I: Introduction
700
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
700
01:38Inflammation
64.6K
Overview
64.6K
01:24Disorders of Hemostasis
2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
01:29Venous Thrombosis III: Interprofessional Care
466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
01:16Clot Retraction and Fibrinolysis
10.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.3K